Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 6/20 | 0.53 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 4/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14734507 | 0.83 | GRIN2B (0.49) | ESR2GRIN2DGRIN3BADRA1DADRA1A | |
| SCHEMBL16902819 | 0.83 | GRIN2B (0.49) | ESR2GRIN2DGRIN3BADRA1DADRA1A | |
| SCHEMBL8008639 | 0.81 | OPRM1 (0.42) | GRIN1 | |
| SCHEMBL5846563 | 0.81 | EPHX2 (0.42) | GRIN1GRIN2B | |
| SCHEMBL6785682 | 0.81 | ALDH1A1 (0.50) | GRIN1GRIN2B | |
| SCHEMBL27979790 | 0.80 | KMT2A (0.50) | — | |
| SCHEMBL5675291 | 0.80 | GBA1 (0.57) | GRIN2B | |
| SCHEMBL12290753 | 0.79 | ESR1 (0.50) | ESR2GRIN2DGRIN3BADRA1DADRA1A | |
| Bicarbonate SCHEMBL2854194 | 0.79 | GBA1 (0.52) | — | |
| SCHEMBL18594867 | 0.78 | P4HB (0.49) | ESR2GRIN2DGRIN3BADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009091433-A2 | SPIRO AND DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2009-07-23 | — | — | WO | disclosed |
| US-20080125441-A1 | SPIRO AND DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2008-05-29 | — | — | US | disclosed |
| US-6313351-B1 | Process for producing alicyclic monoketones and process for producing alicyclic diketones | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2001-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125441-A1 | SPIRO AND DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS | DHODH, THPO, SQLE | ESR2 1687/4885CYP26A1 229/4885GRIN2D 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.